Hexahydro-sila-difenidoJ and eight analogues behaved as simple cumpetitive inhibitors of eHJN·methyl·scopoJamine binding to homogenates frorn human neuroblastoma NB-OK 1 cells (MI sites), rat heart (M 2 sites), rat pancreas (M 3 sites), and rat striatum 'B' sites (M 4 sites). Pyrrolidino-and hexamethyleneimino analogues showed the same sekctivity profile as the parent compound. Hexahydro-sila-difenidol methiodide and the methiodide of p-fluoro-hexahydro·sila-difenidol had a fügher affinity but a lower selectivity than the tertiary amines. Compounds containing a p·methoxy, p-chJoro or p-fluoro substituent in the phenyl ring of hexahydro-sila-difenidol showed a qualitative)y similar selectivity profile as the parent compound (i.e., MI= M 3 = ;"~4 ::;.. M 2 j, but up to 16-fold lower affinities. o-Methoxy-hexahydro-sila-difenidol has a lower affinity than hexahydro-sila-difeni.:!o! at the four binding sites. lts selectivity profile (M 4 > M 1 , M 3 > M 2 ) was different from hexahydro-sila-difenidol.
Introducdon
Musearlnie acetylcholine receptors are currently divided into at least three pharmacologi.cally defined subtypes: M 1 , M 2 (M 2 a) and M 3 (M 2 Jl) receptors (for recent reviews, see Mutschier et al., 1987; Mitchelson, 1988; Levine and Birdsall, 1989) . M 1 receptors are typically found in neuronal tissues (central nervous system and autonomic ganglia), M 2 receptors in lower brain areas (cerebellum) and heart, and M 3 receptors in secretory glands and smooth muscle. This classification is based mainly on the different affinities of musearlnie receptor subtypes for antagonists such as pirenzepine (M 1 > M 3 ~ M 2 ) (Hammer et al.. 1980; Eltze et al .. 1988; Waelbroeck et al., 1988) , AF-DX 116 (Giachetti et al., 1986; Hammer et al., 1986; Micheleui et al., 1987) , methoctramine (Melchiorre et al., 1987; Giraldo et al., 1988) (M 2 > M 1 > M 3 ) and hexahydroCorrespondence to: Jean Christophe., Department of Biochemistry and Nutrition, Medical School, Free University of Brussels, Boulevard of Waterloo 115, B-1000 Brussels, Belgium. sila-difenidol (Lambrecht et al., 1987 (Lambrecht et al., , 1989b \Vaelbroeck et al.. 1987a; Waelbroeck et aL. 1989a; Lazareno and Roberts, 1989 ) (M 3 ~ M 1 > M 2 ). Recently a fourth subtype with high affinity for methoctramine and himbacine. as weil as for hexahydro-sila-difenidol and 4-diphenylacetoxy-Nmethylpiperidine methiodide has been identified in NG108-15 cells (Michel et al., 1989} and rat forebrain (Waelbroeck et al., 1990) . The antagonist binding properties, or the tissue and cell tine distribution of these four pharmacologically defined subtypes correspond closely to that of the recently cloned receptor proteins m1 to m4 (Akiba et al., 1988~ Banner et Peraha et al.. 1987; Buck.ley et al., 1989; Dörje et a1., 1990; Wess et al., in press) .
Using the nonselective antagonist eHJN-methylscopolamine (eH]NMS) as radioligand. we previously demonstrated that over 80% of the muscarinic receptors in the human neuroblastoma NB-OK 1 cellline are of the M 1 subtype (Waelbroeck et al., 1988) . tbat receptors in rat heart are of the M 2 subtype (Waelbroeck et al., 1987a,b) , receptors in rat pancreas beleng to the M 3 subtype (Waelbroeck et al .• 1987a) . and that 85% of tbe 'B' binding sites in rat striatum (Waelbroeck et al.. 1987b ) can be considered as putative M 4 receptors (Waelbroeck et al., 1990) .
The first aim of the present study was to examine the binding properlies of eight hexahydro-sila-difenidol analogues structuralJy modified in the cyclic amino group and the phenyl ring ( fig. 1 ). using the four above-mentioned test systems. The functional antimusearlnie properlies of these muscarinic antagonists have been reported recently (Lambrecht et al., 1989a.b; Waelbroeck et al., 1989a) . All these silicon compounds possess a center of chirality. They were used as racemates since indications were found that silanols (R 3 Si0H) may racemize in aqueous so1ution (Tacke et al., 1987) . The s~cond goal of this study was to investi~ gate the importance of absolute configuration for bind~ ing of hexahydro-sila-difenidol analogues to musearlnie receptors. To achieve this goal we used the configurationally stable (R)-and (S)-enantiomers of the four carbon analogues of 1 b, 4b, Sb and 9b ( -+ compounds la. 4a, 8a and 9a, Fig. 1 ). The functional antimuscarinic properties of the (R)-and (S)-enantiomers of hexahydro-difenidol (la), p-fluoro-hexahydro-difenidol (8a) and their methiodides 4a and 9a have been reported elsewhere (Tacke et al., 1989; Feifel et al.. 1990; . 
Materials and methods

Ce/1 and tissue preparation:;
Human NB-OK 1 neuroblastoma Cl!lls (a generaus gift from Dr. Yanaihara, Shizuoka, Japan) were maintained in RPMI-1640 medium, enriched with 100 U/ml penicillin, 100 l'g/ml Streptomycin and 10% fetal calf serum (from Gibco, Gent, Belgium). Twice a week, the cells were detached by trypsin-EDTA (Gibco, Gent, Belgium) and divided in thirds. For eH]NMS binding experiments, the cells were harvested using a 20 mM sodium phosphate buf!er enriched with 1 mM EDTA and 150 mM NaCI (pH 7.4}, centrifuged at 500 g for 5 min, resuspended and homogenized in 20 mM Tris-HCI buffer enriched with 5 mM MgCI 2 (pH 7 .5) in a glassTeflon homogenizer, and then stored in liquid nitrogen until use.
For cardiac homogenates, male Wist.ar albino rats (200-250 g) were decapitated, the beart immediately removed and rinsed in 150 mM Na.Cl. The homogenization buffer contained 10 mM Tris-HCl (pH 7.5) and 250 mM sucrose. Each heart was homogenized in 2 ml of this buffer with an Ultraturrax homogenizer (maximal speed for 5 s at 4 ° C) followed by further addition of 13 ml of buffer, and seven up and down strokes in a Chemical structure of the carbon,lsilicoo analogues, hexahydro-difenidol (la), hexahydro-sila-difenidol (lb) and their derivatives (2), (3), hexahydro-diferudol methiodide (4a), hexahydro-sila-difenidol methiodide (4b), p-methoxy-hexahydro-sila-difenidol (5), o-methoxy-hexahydrosila-difenidol (6). p<hloro-be.,.··hvdro-::sl~-rii!c:::&i~ü: (7); p-fluoro-hexahydro-difeni<iol (8a), p-fluorohexahydro-sila-d.ifenidol (8b), p-fluoro-hexabydro-difewlol methiodide {9a) and p-fluoro-bexahydro-sila-difenidol methiodide (9b).
g1ass-Teflon homogenizer (at 4 o C). The homogenate was fittered on two layers of medical gauze and either used fresh, or stored in liquid nitrogen until use. For rat brain cortex and striatum homogenates the brain was immediately removed and dissected. The cortex and striatum were homogenized in 15 and 2 ml, respectively, of 20 mM Tris-HCJ buffer (pH 7.5) enriched with 250 mM sucrose, with a glass-Teflon homogenizer, and stored in liquid nitrogen until use. These homogenates were diluted 20-fold with the homogenization buffer before use for eHJNMS binding experiments.
For rat pancreas homogenates the organ was immediately removed, minced with scissors and homogenized in a glass-Teflon homogenizer ( seven up and down strokes at 4 o C) in a solution containing 300 mM sucrose, 0.2 mgjml bacitracin and 500 kallikrein inhibitor U /ml of Trasylol (Bayer, Brussels, Belgium). The resulting homogenate was immediately filtered on two layers of medical gauze and diluted ll~fold with the incubation buffer made of 66 mM sodium phosphate (pH 7.4) enriched with 2.6 mM MgCI 2 , 500 kallikrein inhibitor U jml of Trasylol, 0.2 mg/mJ hacitracin and 13 mg/ml bovine serum albumin.
[ 3 H]NMS binding experiments
eHJNMS binding was measur'!d at 25 o C in a total volume of 1.2 ml using the following incubation buffer: 50 mM sodium phosphate (pH 7.4) enriched with 2 mM MgC1 2 , 1% bovine serum albumin (except when indicated) and the indicated tracer and drug concentrations. Addition of bovine serum albumin to the incubation buffer increased eH]NMS binding very slightly (by at most 10-15%) and improved the reproducibility of duplicates in our filtration assays. In binding experiments on pancreas homogenates, we also added Trasylol and bacitracin (see above) to further inhibit proteolytic activity. Bovine serum albumin was an essential ingredient in pancreas binding studies, since the binding capacity of pancreas homogenates disappeared within 40 min at room temperature if this protein was omitted from the buffer, but was maintained over 90% for at least 4 hin its presence.
To terminate the incubation, each sample was di1uted with 2 ml of ice~cold 50 mM sodium phosphatc buffer (pH 7.4) and filtered on GF jC glass-fiber filters (Whatman, Maidstone, England) presoak.ed in 0.05% polyethyleneimine. The filters were rinsed three tim~ with the same filtration buffer, dried, and the radioactivity {bound uacer) counted by liquid scintillation. This means that tracer binding to striatum M 4 sites in the abscnce of unlabelled drug must be rnaintained below 5% of the total tracer added (i.e., 30% of the 15% initial bindinf>· We therefore decided to use a comparatively high [ H}NMS concentration (0.25 nM. equivalent to five-fold K 0 at M 4 sites) for these experiments.
In binding experL'11ents on rat pancreas homogenates we used 980 111 of the homogenate per 1.2 rnl sample.
The eH}NMS concentration was 0.25 nM (two-fold K 0 in trus system) and protein concentration 800-1000 p.g per assay (about 50 p!\.·f bindiPg sites). An incubation period of 4 h was necessary to allow binding equilibrium.
Protein concentration was measured according to Lowry et aL (19 51) using bovine serum albumin as standard.
Data ana~rsis and sratistics
The competition curves were analyzed using the computer program described by Richardson and Humrich (1984) , and were compatible with the existence of a single receptor type. K 1 values were calculated from IC5<1 values using the Cheng and Prusoff (1973) equa-tion. The pKi value was defined as -log Ki. Each experiment was repeated at least three times. The Standard deviations of each IC 50 value was below 30% of the average va)ue in all cases (corresponding to pK, standard deviations of < 0.1 log unit) and were therefore not mentioned in the tables and figures. The data are presented as rneans of the indicated nurnber of experiments.
Drugs and chemieals
fHJNMS (74 Cijmmole) was obtained from Amersham International (Bucks, EngJand). Atropine, polyethyleneimine and bovine serum albumin (Cohn fraction V) were obtained from Sigma Chernical Co. (St. Louis, MO, U.S. A.) . Tissue culture material and media were obtained from Gibco (Gent. Belgium). All other chemieals were of the highest grade available.
Hexahydro-sila-difenidol (1 b) and the analogues shown in fig. 1 were synthesized in our laboratories ((R)-and (S)-la: Tacke et al., 1989; lb: Tacke et al., 1985; 4b: Waelbroeck et al., 1989a; 2, 3, 5. 6. 7 and Sb were prepared by analogy to the synthesis of 1 b. unpublished results; (R)-and (S)-8a were prepared by anakgy to the synthesis of (R)-and (S)-la, unpublished results; the quaternary ammonium compounds (R)-and (S)-4a, (R)-and (S)-9a as weil as 9b were prepared by quaternization of the corresponding free amines with methyl iodide analogaus to the synthesis of 4b. unpublished TABLEI resuhs). The enantiomeric purity of the enanliomers of la, 4a. Sa and 9a was > 99.7% as detennined on the basis of calorimetric analyses (differential scanning calorimetry) of (R)-and (S)-la (Tacke et al., 1989) and (~.)-and (S)-8a (unpublished results). The experimental procedure (Sarge and Cammenga, 1985; Tacke et al., 198 l. 1989} and data evaluation (Sarge et al., 1988) followed the lines described in the literature.
Results
General considerations
All the competition curves obtained in this study were compatible with the existence of a single receptor subtype in the different preparations with Hili coefficients not significantly different from unity (nH varied between 0.95 and 1.10, with standard deviations below or equal to 0.05). This suggested that eH]NMS Iabelied in each of the tissues homogeneaus binding sites which was not discriminated by the drugs used.
Competition curves with p-chloro-hexahydro-sila-difenidol (7) were shifted to the right by 0.5 to 1 .0 log units in all systems in the presence of bovine serum albumin (1% ). This is illustrated in fig. 2 using cortex homogenates. Almost 10-fold higher concentrations of 7 were needed to inhibit eH)NMS binding in this tissue when 'fraction V' bovine serum albumin was added to Antagonist affinities (pK, values) a of hexahydro-sila-difenidol (lb) and analogues la, 2, 3. 4a, 4b. 5-1, 8a, 8b. 9a the incubation buffer. This suggested that about 90% of compound 7 was bound to bovine serum albumin or a contaminant. Similar results were obtained with p-fluoro--hexabydro--sila-difenidol (8b) and its methiodide (9b) and with the (R)-enanticmers of the corresponding carbon analogues 8a and 9a. We therefore determined the binding affinities of compounds 7, 8a, 8b, 9a and 9b ( Fig. 1) to musearlnie receptors in homogenates from human NB-OK 1 cells, rat heart and striatum in the absence of bovine serum albumin. pKi values are given in table 1. The binding properties of hexahydro-difenidol (la), hexahydro-sila-difenidol (lb) and their analogues 2, 3, 4a, 4b, 5 and 6 ( fig. 1) were hardly affected by inclusion of bovine albunrin into the incubation buffer (pKi increase below 0.3 
log units). This allowed us to perform
binding experiments with these compounds in al1 tissues in the presence of bovine serum albumin (table 1).
Structural variations of rhe amino group
A comparison of binding affmities of (R)-hexahydro-difenidol ((R)-la), hexahydro-sila-difenidol (1 b) and compounds 2/3 and 4aj4b as weil as Saj9a and Sb 1 9b outlined the effect of structural variations of the cyclic amino (ammonium) group on antimuscarinic potency (table 1). Increasing the size of the amino group from pyrrolidino to piperidino (2 -+ 1 b) decreased the affinity for M 1 and (to a lesser extent) M 2 sites. Ex· change of the piperidino by the hexamethyleneimino group (lb-3) decreased the affinities for the four binding sites. N-Methylation of the silicon compounds lb and Sb (-4b and 9b) increased the affinity for the four binding sites, this increase being greatest at M 2 receptors. This N-methylation effect on the affinity of the silicon compounds 1 b and 8b was comparable to or greater than the affinity increase observed with the corresponding (R}-configurated carbon analogues (R)-la (-+ (R)4a) and (R)-8a(-(R)·9a). 
Substitutions on the phenylring
The influence of substituents in the phenyl ring of heJtahydro-siJa-difenidoJ (lb) on binding affinity can be demonstratcd by comparison of the silicon compounds lb, 5, 6, 7 and 8b. as weil as compounds 4b and 9b (table 1) . Introduction of a methoxy substituent in para or ortho position (compounds 5 cmd 6) or a p·chloro substituent (7) reduced the affmity to the musearlnie receptors up to 16-fold (table 1). The influence of a fluoro substituent in para position of hexahydro-siladifenidol (1 b -8b) and its methiodide ( 4b -+ 9b) on affinity was moderate.
4. Sila Substitution
It was not possible to determine exactly the effect of sila substitution on the binding properties of the carbon compounds la, 4a. 8a and 9a from the present results. We did indeed use the pure enantiomers of 1 a, 4a, 8a and 9a in this study but investigated the binding affinities of the racemic mixtures (R/S) of the silicon ana~ logues lb, 4b, 8b and 9b (see introduction). The pK 1 values (table 1) of racemic lb, 4b, 8b and 9b may therefore be lower by at most 0.3 log unit than the pKi vaJues of their high-affinity enantiomers. This is due to the presence of 50% of the low-affmity enantiomers in th~ binding assay. 1f this is taken into account. it is obvious from table 1 tbat Sild-substitution did not significantly affect the binding properties of la, 4a, 8a and 9a at any subtype.
Stereoselectivity
The effect of N-metbylation of (R)· and (S)-hexahydro-difenidol ((R)-and (S)-la; -(R)-and (S}-4a) and (R)-and (S)-p-fluoro-hexahydro-difenidol ((R)-and (S)-8a; -(R)-and (S)-9a} on the affinity for the muscarinic receptor depended on the receptor subtype and on the configuration of the drug (table 2) . In NB-OK 1 cells (M 1 sites), the affmity of both enanti- ')mers of la and 8a was increased two-to threefold by N-methylation (-+ 4a and 9a). In heart (M 2 sites). the affinities of the (R)-enantiomers of 1 a and 8a were increased 10-to 20-fold by N-methylation (-+ 4a and 9a) but the affinities of the (S)-enantiomers were almost unchanged. ln pancreas (M 3 sites). thc affini•ie~ of (R)-hexahydro-difenidol ((R)-la) and its rnethiodide ((R)-4a) were identical but N-methylation decrcased the affinity of the {S)-enantiomers {(S)-la-+ (s)-4a). In striatum (M 4 sites), the affinities of (R)-la. (R)-Sa and (S)-8a were increased two-to fourfold by N-methylation, whereas the affinity of (S)-la was unchanged. p-Fluoro Substitution of the enantiomers of hexahydro-difenidol (la) and its methiodide (4a) changed only slightly (if at all) their affinities for M 1 , M 2 and M 4 sites (table 1). This effect did not depend on the absolute configuration of the compounds.
Discussion
The present study investigated the effects of changing the size of the cyclic amino group (compounds 2 and 3). introducing substituents in the phenyl ring (compounds 5-7, Sb) and N-methylation (compounds 4b and 9b) of hexahydro-sila-difenidol {lb) as well as thc effects of replacing the centrat silicon atom of compounds 1 b, 4b, 8b and 9b by a carbon atom ( com~ pounds la, 4a, Sa and 9a) on musearlnie binding affin~ ity and receptor selecttvity. All :.he compounds tested in this work possess a center of chirality ( central silicon or carbon) and therefore exist in two enantiomers. We had indications that silanols (R 3 Si0H) may racemize in aqueous solution (Tacke et al., 1987) . Thus compounds lb, 2-7, 8b, 4b and 9b were studied as racemates. In contrast, the carbon compounds la, 4a, 8a and 9a (carbinols, R 3 C OH) exist in configurationally stable enantiomers. We took advantage of this by investigating the binding properlies of the individual enantiomers of these compounds at musearlnie receptor subtypes.
Binding properlies of p-fluoro-hexahydro-sila-difenidol
The binding affinities {pK, values, table 1) obtained with most of the hexahydro-sila-difenidol ana1ogues correspond closely to their antimuscarinic potencies (pA 2 values) determined in functional experiments at Mlt M 2 and M 3 receptors (Lambiecht et 1989a,b; Eltze et al., 1988) . We were therefore particularly interested in d1e binding properties of p-fluorohexahydro-sila-difenidol (Sb) which bcbaved in functional experiments as a se1ective M 3 antagonist (M 3 > M 1 > M 2 ) ( Lambrecht et al.. . 1989a Eglen et al., 1989 : Whiting et al., 1989 . In this study we did not find M 1 muscarinic binding sites with a low affinity for p-fluoro-hexahydro-sila-difenidot (Sb) in human neuroblastoma NB-OK 1 cells (labelled by (~H]NMS; table 1) or in rat brain cortex. hippocampus and striatum homogenates Iabeiied by eH)pirenzepine (data not shown).
In contrast. the pK 1 vaJues of p-fluoro-hexahydro-siladifenidol (8b) obtained at cardiac M 2 (6.5) and pancreas M 3 sites (7.8) were in reasonable agreement with the pA 2 values observed in pharmacc!ogical sturlies using isolated guinea-pig atria (M 2 ; 6.0) and ileum (M 3~ 7.S) preparations (Lambrecht et al., , 1989b .
In fact. compound Sb showed a markedly higher affinity for M 1 binding sites in this study (pKi = 7.8; table 1) as compared to functional M 1 receptors in rat ganglia (pA 2 = 7.2). rabbit vas deferens (pA 2 = 6.7) (lambrecht et al., 1988. 1989b) or canine femoral (pA 2 = 7.1) and saphenous vein {pA 2 = 7.1) (Eglen et al., 1989; Whiting et al., 1989) . Our results also contrast with the low affinity of Sb in binding studies using eH]telenzepine-labelled calf Superior cervical ganglia M 1 receptors (Lambrecht et al., 1989a) . We do not have at present a satisfactory explanation fot these differences. Since it was well known that the binding of antagonists to muscarinic M 1 receptors is sensitive to the ionic conditions in the incubation medium (Freedman et al., 1988) we ~ ·neated our binding experi ..-11ents at M 1 receptors in NB OK 1 cells with p-fluoro-hexahydro-sila-difenidol (Sb) using the Tris buffer which was used by Lambrecht et al. (1989a and unpublished data) in binding studies at M 1 receptors of calf superior cervical ganglia. Under these ionic conditions we again found on1y high-affinity binding for compound Sb ( data not shown) in NB-OK 1 cells. An alternative explanation, that M 1 receptors m ganglia and rabbit vas deferens aredifferent frorn M 1 receptors in rat brain and human NB-OK 1 cells seems also unlikely. All the oth~r compounds investigaled in this and other studies {in-cluding the closely related campounds Sa and 9bj b<!d similar affinities for the M 1 binding sites of rat brain and human NB-OK l cells and for the functional {rab-bit vas deferens and ganglia) M 1 receptors (Waelhroeck et al., 1989a; tarnbrecht et al., 1988; 1989a,b; Eltze et al., 1988; Feifel et al., 1990; Lambrecht et al., unpublished results) . uhips When comparing the .structure-binding relationship of hexahydro-süa-difenicol analogues to muscarinic re· ceptor subtypes. these musearlnie antagonists showed some quantitative and qualitative differences in receptor selectivity profiles (table 1) .
The influenee of the ring size of the eyelie amino group on binding affinity and selectivity ean be demonstrated by eomparison of compounds 1 b, 2 and 3. I t is obvious from the data in table 1 that ti•c affinity to the four musearlnie receptor subtypes depends on the strueture of the heterocyclie ring and varies up to fivefold. Compound 2, possessing a pyrrolidino ring shows nearly the same affinity for the four musearlnie receptors as the parent compound hexahydro-sila-difenidol (lb). In eontrast, ring extension to the hexamethyleneimino analogue 3 results in a deciease in affinity, this decrease being greatest at M 3 receptors. However, the influence of the size of the eyelie amino group on receptor seleetivity is moderate as compounds 2 and 3 showed ebout the same selectivity pattem as the parent compound lb:
] and p-fluoro-hexahydro-sila-difenidol (8b-+ 9b) inereased the affinity for M 1 , M 2 and M 4 receptors up to 20-fold, this inerease being consistently greatest at M 2 receptors. In contrast, the affinity of compound (R)-la for M 3 receptors in pancreas was not ehanged by N-methylation, and that of lb was inereased only 2.5-fold. Thus, Nmethylation of the tertiary amines (R)-la. lb, (R)-8a and 8b changed the receptor selectivity pattern from
tors, abolishing the selectivity between M 2 and M 3 receptors. It is interesting to note that the binding affinities of (S)-la and (S)-8a were only slight1y affected by N-methylation at all muscarinic receptor subtypes. It is generally assumed that tertiary antimuscarinic agents interaet in their protonated form with these receptors (Barlow and Chan, 1982; Asselin et al., 1983) . N-Methylation probably does not change the overall charge of the cationic head of the compounds studied: steric faetors due to the presence of an additional N-methyl group may play an important role in the interaction of the quatemary compounds 4a, 4b, 9a and 9b with musearlnie receptors.
We also investigated in this study the effe::.r of Substitution of the phenyl ring in the para and crtho positions. The derivatives of hexahycro-sila-difenidol and hexahydro-difenidol and of their metmodides tested bad equal or lower affinities than the parent compounds (table 1) at the four subtypes. The affinity decreases might be due to steric bindrance, modification of the electron distribution of the molecules, or botb. It is interesting in this respect that the affinities of compounds (R)-laj(R)-.8a, (S)-la/(S)-8a, lbj8b, (R)-4aj(R) = 9a and (S)-4aj(S)-9a were very similar, regardless of the receptor subtype (M 1 , M 2 , l'vf 4 ) studied and of tbe absolute drug configuration. In contrast, 9b bad a two-to threefold lower affinity than 4b for M 1 , M 2 and M 4 receptors. This supports the view that the 101 drug position in the muscarinie binding site is adapted depending on the aetual drug structure, and is not necessarily identical when comparing tertiary and quatemary analogues or C3rbon/silicon bioisosters.
It is noteworthy that the affinity decrease due lo p-chloro substitution (lb _. 7) was greatest at M 2 receptors. Thus, the p-chloro analogue 7 shows a greater selectivity (30-fold) for M 1 /M 3 /M 4 receptors over ~1 2 receptors tnan the parent compound lb. o-Metho>.")'-hexahydro-sila-difenidol (6) presented a unique selectivity profile. It rec.ogzüzed preferentially tbe M 4 receptors, bad an intermediate affmity for M 1 and M 3 receptors and lowest affinity for M 2 receptors.
In general, the (R)-enantiomers of compounds 1 a. 4a. 8a and 9a showed higher binding affinities (up to 398-fold) for the four musearlnie receptor subtypes than the corresponding (S)-configurated isomers (table 1) . How· ever, this stereoseleetivity was not the same for all receptor subtypes. The stereoselectivity ratios (table 2) for the t~'Ttiary eompounds hexahydro-difenidol {la) and its p-fluoro analogue 8a consistently show the same order: M 1 = M":: M 4 > M 2 • This implies that the stereochemical requirements of the musearlnie M 2 receptors are less stringent than that of the other subtypes for the enantiomers of Ja and 8a. Similar resu1ts have been obtained with the enantiomers of other tertiary antimuscarinics such as trihexiphenidyl. hexbutinol, telenzepine or biperiden (for a recent review, see Lambrecht et al.. 1989a; Waelbroeck et al, 1989b) . The stereoselectivity ratios for the tv.·o quaternary compounds 4a and 9a at M 2 receptors are very sirnilar to those of the other subtypes. This is mainly due !o th~ stereoselective effect of N-methylation on the affmity of the (R}-enantiomers of compounds ia and 8a.
In eonc1usion, this report deseribes strueture-activity relationships (induding stereochemical aspeets) of muscarinic antagonists related to hexahydro-sila-difenidol (lb). All compounds behaved as competitive inhibitors of eH]-N-methylscopolamine binding al MI receptorsinhuman neuroblastoma NB-OK 1 cells. r"1z receptors in rat heart as weil as M 3 and M 4 receptors in rat pancreas and striatum, respectiveiy. The binding affinity and receptor selectivity in this series of compounds was fcund to be controlled by the structure of the cyclic amino (arnmonium} group. the substitution pattem of the phenyl moiety and the absolute configuration of the chiral carbinols la, 4a, 8a and 9a. There was little influence of sila-substitution (carbonjsillicon exchange) on binding affinity of these chiral compounds. In con· trast to pharmacological sturlies using isolated organs ~uch as rabbit vas deferens, rat gangiia and canine veins as well as to binding studies in calf ganglia, we could not use p.fluoro-hexahydro-sila-difenidol (8b) to discriminate M 3 from M 1 binding sites, due to the high affinity of this antirnuscarinic agent for M 1 binding sites in homogenates of Nß..OK 1 cells and rat brain.
